137 related articles for article (PubMed ID: 20583207)
1. Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease.
Amuah JE; Hogan DB; Eliasziw M; Supina A; Beck P; Downey W; Maxwell CJ
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):670-9. PubMed ID: 20583207
[TBL] [Abstract][Full Text] [Related]
2. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia.
Daiello LA; Ott BR; Lapane KL; Reinert SE; Machan JT; Dore DD
Am J Geriatr Pharmacother; 2009 Apr; 7(2):74-83. PubMed ID: 19447360
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
[TBL] [Abstract][Full Text] [Related]
4. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
Lu S; Hill J; Fillit H
Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with persistence of cholinesterase inhibitor treatments in the elderly.
Pariente A; Pinet M; Moride Y; Merlière Y; Moore N; Fourrier-Réglat A
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):680-6. PubMed ID: 20583209
[TBL] [Abstract][Full Text] [Related]
6. A population-based study of cholinesterase inhibitor use for dementia.
Herrmann N; Gill SS; Bell CM; Anderson GM; Bronskill SE; Shulman KI; Fischer HD; Sykora K; Shi HS; Rochon PA
J Am Geriatr Soc; 2007 Oct; 55(10):1517-23. PubMed ID: 17697100
[TBL] [Abstract][Full Text] [Related]
7. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
[TBL] [Abstract][Full Text] [Related]
8. Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition.
Kogut SJ; El-Maouche D; Abughosh SM
Pharmacotherapy; 2005 Dec; 25(12):1729-35. PubMed ID: 16305292
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of rivastigmine in routine clinical practice.
Frankfort SV; Appels BA; de Boer A; Tulner LR; van Campen JP; Koks CH; Beijnen JH
Int J Geriatr Psychiatry; 2005 Dec; 20(12):1167-71. PubMed ID: 16315150
[TBL] [Abstract][Full Text] [Related]
10. Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil.
Hatoum HT; Thomas SK; Lin SJ; Lane R; Bullock R
J Med Econ; 2009 Jun; 12(2):98-103. PubMed ID: 19492974
[TBL] [Abstract][Full Text] [Related]
11. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease.
Feldman HH; Pirttila T; Dartigues JF; Everitt B; Van Baelen B; Schwalen S; Kavanagh S
Int J Geriatr Psychiatry; 2009 May; 24(5):479-88. PubMed ID: 18985627
[TBL] [Abstract][Full Text] [Related]
12. Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease.
Haywood WM; Mukaetova-Ladinska EB
Am J Geriatr Pharmacother; 2006 Sep; 4(3):273-86. PubMed ID: 17062329
[TBL] [Abstract][Full Text] [Related]
13. A qualitative analysis of the mini mental state examination on Alzheimer's disease patients treated with cholinesterase inhibitors.
Lucchi E; Minicuci N; Magnifico F; Mondini S; Calza A; Avanzi S; Villani D; Bellelli G; Trabucchi M
Arch Gerontol Geriatr Suppl; 2004; (9):253-63. PubMed ID: 15207422
[TBL] [Abstract][Full Text] [Related]
14. Cholinesterase inhibitor use in Alzheimer's disease: the EPIFARM-Elderly Project.
Franchi C; Lucca U; Tettamanti M; Riva E; Fortino I; Bortolotti A; Merlino L; Pasina L; Nobili A
Pharmacoepidemiol Drug Saf; 2011 May; 20(5):497-505. PubMed ID: 21432941
[TBL] [Abstract][Full Text] [Related]
15. Anticholinesterase duration in the Australian veteran population.
Gadzhanova S; Roughead L; Mackson J
Aust N Z J Psychiatry; 2010 May; 44(5):469-74. PubMed ID: 20397790
[TBL] [Abstract][Full Text] [Related]
16. Hypertension, white matter change and response to cholinesterase inhibitors in Alzheimer's disease.
Connelly PJ; Prentice NP; Fowler KG
Int J Geriatr Psychiatry; 2005 Jul; 20(7):623-8. PubMed ID: 16021654
[TBL] [Abstract][Full Text] [Related]
17. Cholinesterase Inhibitor Utilization: The Impact of Provincial Drug Policy on Discontinuation.
Fisher A; Carney G; Bassett K; Chappell NL
Value Health; 2016; 19(5):688-96. PubMed ID: 27565287
[TBL] [Abstract][Full Text] [Related]
18. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study.
Bourgault C; Sénécal M; Brisson M; Marentette MA; Grégoire JP
J Hum Hypertens; 2005 Aug; 19(8):607-13. PubMed ID: 15920457
[TBL] [Abstract][Full Text] [Related]
19. A 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer's disease in Europe : predictors of discontinuation and switch in the ICTUS study.
Gardette V; Lapeyre-Mestre M; Piau A; Gallini A; Cantet C; Montastruc JL; Vellas B; Andrieu S;
CNS Drugs; 2014 Feb; 28(2):157-70. PubMed ID: 24408842
[TBL] [Abstract][Full Text] [Related]
20. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition.
Lopez OL; Becker JT; Saxton J; Sweet RA; Klunk W; DeKosky ST
J Am Geriatr Soc; 2005 Jan; 53(1):83-7. PubMed ID: 15667381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
